[A25-138] Avapritinib (gastrointestinal stromal tumours) – Benefit assessment according to §35a Social Code Book V
Last updated 02.02.2026
Project no.:
A25-138
Commission:
Commission awarded on 31.10.2025 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
DOI:
https://doi.org/10.60584/A25-138
| Project no. | Title | Status |
|---|---|---|
| G23-32 | Avapritinib (indolent systemic mastocytosis) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V | Commission completed |
| G22-10 | Avapritinib (advanced systemic mastocytosis) – Assessment according to §35a (para. 1., sentence 11) | Commission completed |
| G20-26 | Avapritinib (GIST) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V | Commission completed |
| A25-137 | Avapritinib (advanced systemic mastocytosis) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A25-136 | Avapritinib (indolent systemic mastocytosis) – Benefit assessment according to §35a Social Code Book V | Commission completed |